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Abstract
Objectives—To identify SNPs associated with switching from an ACE-inhibitor to an 
angiotensin receptor blocker (ARB).
Methods—Two cohorts of patients starting ACE-inhibitors were identified within the Rotterdam 
Study in the Netherlands and the GoDARTS study in Scotland. Cases were intolerant subjects who 
switched from an ACE-inhibitor to an ARB, controls were subjects who used ACE-inhibitors 
continuously for at least 2 years and did not switch. GWAS using an additive model was run in 
these sets and results were meta-analysed using GWAMA.
Results—972 cases out of 5 161 ACE-inhibitor starters were identified. 8 SNPs within 4 genes 
reached the GWAS significance level (P<5×10-8) in the meta-analysis (RBFOX3, GABRG2, 
SH2B1 and MBOAT1). The strongest associated SNP was located in an intron of RBFOX3, which 
contains a RNA binding protein (rs2061538: MAF=0.16, OR=1.52[95%CI: 1.32-1.76], 
p=6.2x10-9).
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Conclusions—These results indicate that genetic variation in abovementioned genes may 
increase the risk of ACE-inhibitors induced adverse reactions.
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Introduction
Angiotensin converting enzyme inhibitors (ACE-inhibitors) are one of the most frequently 
prescribed groups of medications for the management of high blood pressure, heart failure 
and renal disease [1]. While ACE-inhibitors are generally prescribed for lifetime treatment, a 
cohort study showed that 32.4% of patients halted their medication likely due to adverse 
drug reactions (ADRs) within a median 336 days follow up time [2]. The most common 
ACE-inhibitor induced ADR is a persistent, dry cough and the most severe one is life 
threatening angioedema of lips, tongue and upper airway [3]. There is evidence suggesting 
genetic predisposition to these ADRs; ACE-inhibitor induced cough occurs with higher 
incidence in East Asian patients (23%) compared with Caucasians (5–11%) [4, 5]. The 
ACE-inhibitor induced angioedema rate is higher in black patients than in white patients and 
angioedema patients often have affected relatives [6, 7].
The mechanism of ACE-inhibitor induced cough and angioedema is not completely 
understood. ACE-inhibitors inhibit Angiotensin I Converting Enzyme (ACE) that cleaves 
several target proteins including angiotensin I and pro-inflammatory kinins. The blood 
pressure modification takes place through angiotensin I [8]. Accumulation of these 
inflammatory kinins is hypothesized to be the main reason of ACE-inhibitor induced 
angioedema and cough [9, 10]. For two decades, multiple candidate genes studies have 
tested the associations between ACE-inhibitor induced cough and genetic variation in ACE 
and bradykinin pathways, of which the insertion-deletion (I/D) variation in the ACE gene 
has been investigated most frequently [11–14]. A meta-analysis of 12 such studies, did not 
find a statistically significant association for the ACE I/D polymorphism [15]. Studies on 
ACE-inhibitor induced angioedema have also been conducted with the same approach; 3 of 
them found a statistically significant association between ACE-inhibitor induced 
angioedema and single nucleotide polymorphisms (SNPs) in the XPNPEP2 gene [16–18]. 
One study showed that the bradykinin receptor2 (B2) -9/+9 polymorphism is associated with 
both ACE-inhibitor induced cough and angioedema [19]. However generally, most of the 
candidate gene approach studies have been difficult to replicate and their results should be 
interpreted with caution [20]. The only genome wide association study (GWAS) on 175 
ACE-inhibitor induced angioedema cases and 489 controls that also used ACE-inhibitors, 
found no genome-wide association, which might be due to the small sample size [21]. For 
ACE-inhibitor induced cough, the only GWAS with 1 595 cases and 5 485 controls 
identified genome-wide significant associations in KCNIP4 gene at chromosome 4 
(rs145489027, p=1.0x10-8) which was replicated in 2 independent populations [22].
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Based on the probable similar mechanism of ACE-inhibitor induced ADRs (cough and 
angioedema), this study aims to use a GWAS approach to identify SNPs associated with 
intolerance of ACE-inhibitors defined as switching of an ACE-inhibitor to an angiotensin 
receptor blocker (ARB) as a marker for ADRs [23].
Methods
Study population
This study was performed in 2 separate European populations:
A) The Rotterdam study in the Netherlands has been described in detail previously 
[24, 25]. In summary, it is an ongoing cohort, composed of three different sub-
cohorts (RS1, RS2, and RS3), started in 1990 in Ommoord a suburb of 
Rotterdam that has included 14 926 subjects aged 45 years or older (72.0 % of 
20 744 eligible invited people). The Rotterdam Study has been approved by the 
medical ethics committee according to the Wet Bevolkingsonderzoek: ERGO 
(Population Study Act: Rotterdam Study), executed by the Ministry of Health, 
Welfare and Sports of the Netherlands. All participants gave informed consent to 
participate in the study and to obtain information from treating physicians and 
pharmacies, separately.
B) The (Go-DARTS study) which is a genetic sub-study of The Diabetes Audit and 
Research Tayside, Scotland (DARTS) that has been described and validated in 
previous publications [26]. In summary, this project was based on linking 
clinical records by a patient-specific identifier, allowing the creation and 
maintenance of sophisticated regional health informatics systems. The DARTS 
project electronically followed all residents in Tayside, since January 1996 
(n=391 274 including 7 596 individuals with diabetes) through linking the 
clinical datasets with a high degree of reliability and accuracy. Collection and 
analysis of data in DARTS and Go-DARTS was approved by the East of 
Scotland Research and Ethics Committee, in compliance with the declaration of 
Helsinki.
Phenotype
For both study populations similar phenotype definitions were applied for cases and control 
selection:
Cases: Patients who switched to an ARB during ACEI treatment.
Controls: Patients, who started ACE-inhibitors, and continued treatment for at least 2 years. 
They did not discontinue or switch their ACE-inhibitors during the follow up.
For defining continuation, discontinuation or switching, a maximum of 6 months gap 
between 2 prescription periods was considered. These definitions were validated in our 
previous study as the best marker of ACE-inhibitor induced ADRs within the prescription 
databases [23].
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Genotyping
Within the Rotterdam study a total of 12 453 subjects were genotyped with Illumina 
500(+duo) and Illumina 610 quad and 11 496 subjects passed genotyping quality control. 
Exclusion criteria for SNPs were a call rate <98%, Hardy-Weinberg p-value <1 × 10-6, 
minor allele frequency <0.01%, excess autosomal heterozygosity >0.336, sex mismatch and 
outlying identity-by-state clustering estimates. Data was imputed with the 1000-Genomes 
reference panel (phase 1, version 3) using MACH version 1.0.15/1.0.16.
Within the Go-DARTS study, subjects were genotyped on the Affymetrix 6.0 (Affymetrix, 
Santa Clara, CA, USA) or Illumina HumanOmniExpress (Illumina, San Diego, CA, USA) 
platforms. Both platforms were imputed using IMPUTE2 and the 1000 Genomes reference 
panel [27]. Subjects were excluded if they fulfilled any of the following criteria: SNPs call 
rate < 95%, sample call rate < 95%, outliers identified by IBS clustering analysis and gender 
discordant individuals. SNPs deviating from Hardy–Weinberg equation (P<1 × 10-6) or with 
an Info Score <0.4 were excluded.
Data analyses
The primary single SNP tests of association were performed using logistic regression 
assuming an additive genetic model, adjusting for age and gender. PLINK v1.07 was used 
for the Dutch cohort [28] and SNPTEST-v2.5-beta was used for the Scottish cohort [29]. 
The fixed effect meta-analyses were done at both sites using the inverse variance weighting, 
in the Netherlands using METAL and Scotland using GWAMA [30, 31]. The final SNP list 
in the Netherlands analysis was filtered based on the index of heterogeneity (I2 <60) and the 
number of cohorts that covered a SNP (more than two cohorts) [32]. The final values 
presented in this study are from the analyses in Scotland because GWAMA provides the 
odds ratios and does not require further calculations; however the consistency of the results 
at both sites was considered for the most significantly associated SNPs. Data of SNPs 
around the most significant gene were visualized using LocusZoom [33]. All other analyses 
were performed using SAS v9.3 (SAS Institute, Cary, NC, USA). R packages were used to 
plot the graphs. Metafor R package used for forest plot [34] and qqman package for 
Manhattan and QQ plot [35].
Results
A total of 710 cases of ACE-inhibitor intolerant patients and 3 599 tolerant controls in the 
Genetics of Diabetes Audit and Research in Tayside Scotland (Go-DARTS) population and 
262 cases and 590 controls in the population of the Rotterdam study were analysed 
separately and subsequently meta-analysed. 2004 patients from Go-DARTS population were 
genotyped using the Illumina chip (GD1) and the rest (2305 patients) were genotyped using 
the Affymetrix chip (GD2). Three sub populations within Rotterdam study, RS1, RS2 and 
RS3 had 630, 170 and 52 patients respectively). In both cohorts the mean age of included 
patients was not statistically significantly different between cases and controls. The 
proportion of females was significantly higher within cases compared to controls in both 
cohorts (Table 1).
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In the meta-analysis of both cohorts using multivariable regression analyses adjusting for 
gender and age, 8 SNPs located on chromosome 5 (one SNP), 6 (one SNP), 16 (one SNP) 
and 17 (five SNPs) reached genome-wide significance level (P-value less than 5x10-08) 
(Figure 1 and 2). Table 2 shows the details of the most statistically significantly associated 
SNPs. From these SNPs, two were only available in the Go-DARTS population 
(rs192613545 and the insertion/deletion polymorphism on chromosome 17 position 
77112502). A List of the most significantly associated SNPs which reached P-value of less 
than 10-05 in meta-analysis, is available in the supplement in Table 1. The most significantly 
associated SNP (rs2061538) was located within the gene RBFOX3 (RNA Binding Protein, 
Fox-1 Homolog (C. Elegans) 3). There were several other strongly associated SNPs in high 
linkage disequilibrium (LD) with this SNP in that region (Figure 3A). The second most 
statistically significant SNP (rs77370934) was located within the gene GABRG2 (Gamma-
Aminobutyric Acid Receptor Subunit Gamma-2), however, there were no other SNPs with a 
high level of LD in that locus (Figure 3B).
There were also genome wide statistically significant SNPs within the MBOAT1 gene 
(Membrane Bound O-Acyltransferase Domain Containing 1) and SH2B1 gene (SH2B 
Adaptor Protein 1).
Figure 4 presents the odds ratio and the 95% confidence interval (95% CI) for the two most 
statistically significantly associated SNPs for the different sub studies of the Rotterdam 
study and the Go-DARTS population. Except for the RS3 which is the smallest 
subpopulation, the effect directions were concordant between the populations.
A high level of consistency was observed for the meta-analyses results from both sites using 
the GWAMA and METAL, particularly for the most significantly associated SNPs.
Discussion
Our study describes a large GWAS study investigating SNP variants associated with 
switching of an ACE-inhibitor to an ARB as a marker for ACE inhibitor induced ADRs. All 
phenotype data for this study were derived from clinical settings that incorporate either the 
prescription data system (GoDARTS) or the pharmacy drug dispensing database (Rotterdam 
study). We found statistically significant associations with SNPs located within the genes 
RBFOX3, GABRG2, SH2B1 and MBOAT1. These are novel candidate genes which may 
play a role in the adverse drug reactions to ACE-inhibitors.
The SNPs showing the strongest association with the phenotype are located on chromosome 
17 within the gene RBFOX3. This is a member of the RBFOX family that in mammals 
consists of three members: RBFOX1, RBFOX2 and RBFOX3. RBFOX3 is expressed 
specifically in neuronal cells. This protein contains an RNA recognition motif that binds 
specifically to an RNA element, UGCAUG and regulates alternative pre-mRNA splicing. 
Alternative splicing of pre-mRNA is an important mechanism for post-transcriptional 
regulation of gene expression and has increasingly been appreciated as a major mechanism 
to generate diversity of gene products in higher eukaryotes [36, 37].
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The other most strongly associated SNP was located on chromosome 5 within the gene 
GABRG2 which encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major 
inhibitory neurotransmitter in the mammalian nervous system, where it acts at GABA-A 
receptors. GABA-A receptors are pentameric, consisting of proteins from several subunit 
classes: alpha, beta, gamma, delta and rho [38]. There are several studies proving the effects 
of GABA receptor agonists in decreasing the sensitivity to cough both in animal models and 
in humans. This makes them a possible target for cough treatment [39]. Dicpinigaitis et al 
showed that Baclofen (as a GABA receptor agonist) can supress cough induced by ACE-
inhibitors [40]. They also proved in a prospective clinical trial that baclofen can inhibit 
capsaicin-induced cough [41].
SH2B1 (sarcoma (Src) homology 2 (SH2) B adaptor protein 1) is a member of a family of 
scaffold proteins implicated in signalling downstream of a variety of receptor tyrosine 
kinases and cytokine receptors [42]. Variations in this gene have been reported to be 
associated with obesity [43]; however its role in the abnormal glucose homeostasis has not 
been proved [44]. The significant association of this gene with the intolerance of ACE-
inhibitors needs to be further investigated because there was no previous report of this gene 
contributing in cough or angioedema.
MBOAT1 (membrane bound O-acyltransferase domain containing 1) belongs to the 
superfamily of MBOAT that transfer organic compounds, usually fatty acids onto hydroxyl 
groups of membrane-embedded targets [45]. This trans-membrane protein has been reported 
to be involved in developmental processes [46].
The main hypothesized mechanism of ACE-inhibitor induced ADRs (mainly cough and 
angioedema) is stimulation of sensory nerve resulting from the accumulation of 
inflammatory mediators that are normally cleaved by the ACE [3]. This hypothesis has 
served as the basis for candidate gene studies that have focused on variation in inflammatory 
pathways, however findings of those candidate gene studies were replicated inconsistently 
and the meta-analyses of loci that had enough studies, did not find the significant effect for 
the insertion/deletion polymorphism within ACE gene [15]. Hypothesis free GWA studies 
may lead to finding novel loci to be associated with ADRs of ACE-inhibitors. The only 
available large GWAS on ACE-inhibitor induced cough found an association with Kv 
Channel Interacting Protein 4 (KCNIP4) which is predominantly expressed in nervous 
systems [22]. However the only available GWAS on the ACE-inhibitor induced angioedema 
with 175 ACE-inhibitor induced angioedema cases and 489 controls could not find any 
significant association on a genome wide level which could be due to the relatively small 
sample size and lack of the power [21]. Our results suggest that an important source of 
variation may be directly related to the sensory nerves themselves, because both GABRG2 
and RBFOX3 genes are playing a role in the central and peripheral nervous systems as well. 
These findings are in line with the previous GWAS on ACE-inhibitor induced cough [22].
This study is a large GWAS on the intolerance of ACE-inhibitors within a population of 
European ancestry. However the direct relevance of our findings with ACE-inhibitor induced 
ADRs is not clear yet and needs to be further investigated, these findings, if replicated in 
other populations, can improve our understanding of the biological mechanism of ACE-
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inhibitor induced ADRs. Furthermore, it will help to identify those patients at high-risk to 
develop ACE-inhibitor induced ADRs including angioedema, which is a life threatening 
event. We recently showed that approximately 50% of ACE-inhibitor users continue ACE-
inhibitors after the first episode of angioedema [47]; Identification of those patients at high 
risk could help physicians guide their treatment choice. ACE-inhibitor induced cough is not 
as life threatening as angioedema but it can be misdiagnosed and mistreated which 
significantly decreases the compliance of patients and might finally result in unsuccessful 
drug therapy [48, 49]. Therefore in the context of precision medicine, the ultimate 
application of these findings within the clinic would be the prediction of susceptible patients 
and treating them with an alternative medication with comparable effect such as ARBs [50].
An important limitation of this study is defining phenotype based on the electronic medical 
records which can potentially lead to misclassification of cases and controls. However in a 
validation study, the proxy marker for cases showed a positive predictive value of 68.3% for 
probable ACE-inhibitor induced ADRs [23]. This study also cannot detect associations for 
rare SNPs (MAF< 0.01%). The study results are restricted to the European ancestor 
populations.
In conclusion, this study used a GWAS to identify SNP variants associated with ACE-
inhibitor intolerance as a marker of ADRs. We identified SNPs in the genes RBFOX3, 
GABRG2, SH2B1 and MBOAT1 as potential candidates for ACE inhibitor induced ADRs. 
Due to the fact that this is a hypothesis generating study, the functional role of significantly 
associated genes was not investigated; therefore future studies are needed to replicate our 
findings in addition to the epigenetic and molecular studies are needed to explore the 
functional roles of variations within genes reported in this study specifically the GABRG2 
gene for which several clinical studies also showed its role in susceptibility to cough [39–
41]. The standard clinical criteria have been described for ACE-inhibitor induced 
angioedema [51] and to make it possible to combine results it would be good if new genetic 
association studies would use this standard phenotype in the future.
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Figure 1. 
Manhattan plot of genotyped SNPs associated with ace-inhibitor intolerance using an 
additive model adjusted for age and gender. The red line indicates the genome-wide 
significance threshold of alpha=5x10-8.
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Figure 2. 
A QQ plot for SNP associations from a meta-analysis of GWAS of ACE-inhibitor 
intolerance using an additive model adjusted for age and gender. (Lambda=0.88)
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Figure 3. 
LocusZoom plot of most strongly associated SNPs from the meta-analysis located in A) the 
region of most significantly associated genes
A) The RBFOX3 (chromosome 17 centred around SNP rs2061538 (shown in purple). 
Linkage disequilibrium (based on r2 values) with respect to rs2061538 are based on the CEU 
reference population.
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B) The GABRG2 (chromosome 5 centred around SNP rs77370934 (shown in purple). 
Linkage disequilibrium (based on r2 values) with respect to rs77370934 are based on the 
CEU reference population.
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Figure 4. 
The forest plot from the meta-analyses of most strongly associated SNPs
GD: GoDARTS, RS: Rotterdam study, CI: confidence interval
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Table 1
General characteristics of the included ACE-inhibitors starters
GoDARTS Rotterdam study
Case (n=710) Control (n=3599) P-value Case (n=262) Control (n=590) P-value
gender Male 51.4% 59.8% <0.001 33.59% 53.2% <0.001
Female 48.6% 40.2% 66.41% 46.8%
Mean age years [SD] 62.77 [9.98] 62.45 [10.84] 0.4631 64.47 [6.79] 65.15 [7.69] 0.2177
SD: standard deviation
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Table 2
Most significantly associated SNPs
SNP Chr Position MA MAF OR 95% CI P-value Gene
rs2061538 17 77112562 G 0.16 1.52 1.3-1.7 6.2x10-09 RBFOX3
rs77370934 5 161604254 G 0.03 3.16 2.1-4.6 7.7x10-09 GABRG2
rs56209714 17 77113268 G 0.14 1.54 1.3-1.7 7.9x10-09 RBFOX3
rs192613545 16 28863901 T 0.07 2.33 1.7-3.1 2.5x10-08 SH2B1
chr17:77112502:I 17 77112502 C 0.14 1.62 1.3-1.9 2.7x10-08
rs62063838 17 77114028 C 0.17 1.47 1.2-1.6 3.7x10-08 RBFOX3
rs10946364 6 20177222 T 0.39 1.34 1.2-1.4 3.8x10-08 MBOAT1
rs56044629 17 77109653 G 0.14 1.51 1.3-1.7 4.2x10-08 RBFOX3
SNP: single nucleotide polymorphism, Chr: chromosome, MA: minor allele, MAF: minor allele frequency, OR: odds ratio, CI: confidence interval,
A List of the most significantly associated SNPs which reached P-value of less than 10-05 in meta-analysis, is available as the supplementary 
material.
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